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ABSTRACT 
The research of this thesis is focused to investigate the role of SUMOylation, a protein 
post-translational modification reaction, implemented to the skeletal muscle 
pathophysiology area. SUMOylation is regulated by an enzymatic cascade of coordinated 
events capable of the reversible attachment of the Small Ubiquitin-like Modifier (SUMO) 
on to the targeted proteins. This reaction is highly susceptible to intra- or extracellular 
stimuli and responds immediately by altering the expression of its enzymes and the final 
SUMOylated products as an adaptation to the new status.  
Skeletal muscle is a complex organ and it is unfortunately affected by severe diseases, 
which represent widespread pathologies affecting millions of people every year. Until 
now, despite many studies performed on the field, there is still a lack of information about 
the cellular and molecular mechanisms predicting or describing the early events of human 
muscle pathologies. We investigated different processes occurring among the SUMO 
network and the skeletal muscle functions and related them to the normal muscle 
activities or muscle alterations, from rodent models of muscle pathologies to human 
muscle biopsies. We described a tight correlation between the abundance of SUMO 
conjugated proteins and the different skeletal muscle fiber types. This association was 
quickly altered as a consequence of muscle activity changes or early events in acquired 
muscular disorders. We provided also a new skeletal muscle embryological classification 
based exclusively on the diverse abundances and distribution of the SUMO enzymes.  
A combination of innovative techniques allowed us to identify and validate new 
SUMO skeletal muscle targets and determine the modulation of the SUMO enzymes 
abundances during myogenesis and the progression of acquired muscle diseases. These 
results assigned to some SUMO components a potential biomarker function to predict 
skeletal muscle dysfunctions.  
Thus, the investigation on skeletal muscle disuse allowed us to discover a new 
transcriptional regulation mechanism of the E2 SUMO enzyme, Ubc9, mediated by the 
transcriptor factor PAX6 in soleus muscles under unloaded conditions.  
Finally, we proved that targeting the SUMO pathway using chemical drugs as BGP-
15 or anacardic acid have a positive effect on the treatment of myopathies and improving 
myogenesis under hyperglycemic conditions.  
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INTRODUCTION  
Skeletal muscle is a developed composite structure important for our life. The 
complexity of this organ is maintained by regular body training that promotes the good 
health of the muscle. Unfortunately, modifications in the lifestyle or mutations in the 
human genome promotes muscle disorders. To understand how these changes contributed 
to altering the ordinary skeletal muscle functions, I present in this thesis a new concept 
focused to investigate the role of the SUMO protein posttranslational modification in 
muscle pathophysiology. 
1. MUSCLE 
Muscle is one of the main soft tissues present in the animal kingdom. It is in charge of 
generating motion, maintaining body posture, and temperature homeostasis. Muscle cells 
also produce and secrete specific cytokines called myokines1,2. Muscle is categorized into 
three different types according to cell structure and function: cardiac, skeletal, and smooth 
(Figure 1). 
 
Figure 1: Types of muscle. The three types of muscles in the body, cardiac, skeletal, and 
smooth with their cellular organization. Blueringmedia, Vectorstock3.  
Cardiac muscle is formed by single striated cells with multiple branches and forms the 
major contractile tissue of the heart. Skeletal muscles are formed by multinucleated 
striated cells with a linear organization and gather the majority of the limbs, diaphragm, 
and neck-head muscles. Smooth muscle cells lack striation and form part of the inner 
structures of blood vessels, the uterine system, and the respiratory and digestive tracks. 
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Muscle cells contract in response to signals sent by the nervous system. Skeletal 
muscle cells receive the signal from the central nervous system causing a voluntary 
contraction in response to conscious orders, while cardiac and smooth cells receive the 
signal from the autonomic nervous system and contract involuntarily4.  
1.1. Skeletal muscle 
Skeletal muscle forms the 30-50% of total human body weight and stores about 50-
75% of all human body carbohydrates and amino acids. These compounds are released 
into the blood to maintain constant glucose levels during starvation since the release of 
amino acids stimulates the secretion of insulin and glucagon5,6. The skeletal muscle 
consists of different integrated components: blood vessels, nerve fibers, connective tissue, 
and muscle fibers. The blood vessels provide nutrients, oxygen, and remove the metabolic 
residues. Nerve fibers send the contraction signals to the muscle. The connective tissue 
helps the muscle to maintain its structure creating different organized structural levels of 
myofibers, muscle fascicle, and skeletal muscle (Figure 2).  
 
Figure 2: Striated muscle; human biceps muscle. Structural levels of the muscle 
organization, from muscle to the sarcomere. Encyclopӕdia Britannica7. 
Myofibers are long and cylindrical cells with multiple flattened nuclei in the periphery 
and surrounded by the myofiber cell membrane, the sarcolemma, that is enveloped by the 
basal lamina and connective tissue. Sarcolemma acts as a barrier between the extra- and 
intracellular spaces, allows the nutrients transport through different channels, maintains 
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the cell architecture and force transmission, and conducts the action-potential stimuli 
through the T-tubes. The T-tubes are membrane invaginations that permit a faster 
transmission of the action-potential into the muscular cells and help in the intracellular 
calcium regulation. Sarcoplasm, the muscle cell cytoplasm, contains myofibrils, glycogen 
for energy supply, and hemoglobin for gas exchange. More, sarcoplasm has a great 
abundance of mitochondria to fulfill high energy demand, and it is traversed by the 
sarcoplasmic reticulum, which forms a tight network storing calcium ions for the muscle 
contraction.  
The myofibrils constitute the contractile structures through the repetition of sections 
called sarcomeres that give the striated appearance to the cardiac and skeletal muscles. 
Sarcomeres possess a highly organized arrangement of the contractile filaments, actin and 
myosin, and the regulatory proteins troponin and tropomyosin8. The sarcomere anatomy 
is described according to the observations using electron microscopy (Figure 3).  
 
Figure 3: Striated muscle sarcomere. Schematic diagram. A-band of myosin filaments 
crosslinked with thin actin-containing filaments that end at the Z-disc (a). Nebulin 
(green) and titin (red) contribute to the structure. Electron micrograph of a longitudinal 
section of fish white (fast) muscle (b). Scale bar = 500 nm. Pradeep K Luther, J. Muscle 
Res. Cell Motil, 200910. 
Indeed, the muscle fiber shows a dark middle band framed by two light zones. The 
dark zone, name as A-bands, is caused by high protein density corresponding to thick 
filaments overlapping with the thin filaments. A different zone, the M-line, localized in 
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the middle possess connective tissue merged with the thick filaments to maintain the 
structure. The lighter zones (I-bands) have less protein density and have a dense band (Z-
disk) in the middle with connective tissue merged with the thin filaments9. The region 
contained between Z-disks is defined as a sarcomere. 
1.1.1.  Myosin 
Myosins (500 kDa) are a big superfamily of motor proteins and the human genome 
encode more than 40 MYO genes belonging to 11 clases11. They interact with actin to 
produce muscle contraction and are involved in other activities like cell movement, 
transport of organelles, and mitosis. Myosins are divided into 3 regions, an N-terminus 
head with ATPase activity for the binding and movement over the actin filaments, a 
middle region, and the C-terminus tail12. Myosin II is the most common class, it is 
responsible for muscle contraction, and can be found in striated and smooth muscle cells 
and forming stress fibers in non-muscular tissues13. It is composed of two heavy chains 
forming the double head and the coiled-coil tails and four light chains forming the middle 
regions and binding the heavy chains14,15.  
1.1.2.  Actin  
Actin (42 kDa) is a highly expressed protein in the cells and can be found in two 
different states, monomeric (G-actin), or combined in a polymeric filamentous chain (F-
actin). Actin can perform protein-protein interaction with a vast amount of actin-binding 
proteins, making it a key player in multiple functions within the cell16. There are 5 actin 
isoforms, 3 α-isoforms expressed in each of the three muscle types (smooth, skeletal, and 
cardiac), and a β- and γ-isoforms in all the cells, with slight amino acid differences among 
them mainly close to the N-terminus. The combination of two F-actin filaments forming a 
helicoidal structure is essential for the contractile force production. 
1.1.3.  Troponin 
Troponin is a specific protein complex of skeletal and cardiac muscles. There are 
three regulatory units in the complex: troponin T (34 kDa), troponin I (23 kDa), and 
troponin C (18 kDa), with different functions. Troponin T anchors the troponin complex 
to tropomyosin. Troponin I binds the troponin-tropomyosin complex to the actin filament 
and blocks the actin-myosin interaction in the absence of calcium. Troponin C possesses 
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calcium-binding sites and induces the conformational change of troponin I to start the 
contraction17. 
1.1.4.  Tropomyosin 
Tropomyosin (70 kDa) has four tropomyosins (TPM) genes that generate 40 isoforms 
in mammals. Tropomyosin is localized in the myosin-binding sites of the actin proteins, 
blocking them. When the calcium levels rise and the contraction process begins, troponin 
rotates tropomyosin position freeing the myosin-binding sites on actin18. 
1.2. Myogenesis 
Myogenesis is the process that promotes skeletal muscle formation during embryonic 
development but also in any other circumstances when muscle regeneration or reparation 
is required, like injuries or muscle remodeling. In embryonic development, a high 
abundance of fibroblast growth factors (FGFs) are produced inducing the myoblast 
proliferation process, consequently, when the FGFs levels decrease, the myoblast division 
is arrested and the myogenesis program begins. During muscle regeneration, activated 
satellite stem cells respond to the cytokines released from the immune cells as 
inflammatory signals to repair the damaged myofibers19. The satellite stem cells will 
follow an asymmetric division with one of the daughter cells remaining as stem cell and 
the other starting the differentiation into the myogenic pathway to provide enough cells to 
heal the fiber20. When muscle reparation occurs due to a severe injury condition, muscle 
regeneration is associated with fibrosis events that contributed to repair the area, replacing 
the damaged myofibers with connective tissue.  
Myogenesis is a highly regulated event. Indeed, the gene expression of myogenic 
regulatory factors (MRFs) such as MyoD, Myf5, and Mrf4 are indispensable for skeletal 
muscle development. Satellite stem cells expressing high levels of Myf5 and Pax7 will 
follow the myogenic pathway21. Pax is a family of transcription factors with an important 
role in tissue specification and organ development22. An increase of MyoD gene 
expression regulated by Pax7 will induce the proliferation, differentiation, and muscle 
regeneration. Myogenin is also part of the MRF family with a later role in the 
differentiation of myoblasts into skeletal muscle fibers23(Figure 4).  
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Figure 4: The myogenic regulatory factors pathway during skeletal muscle regeneration. 
Myogenesis steps from quiescent cells to mature myofibers. Expression of the different 
MRFs and Pax7 during the different stages. Nadège Zanou et al., Cellular and Molecular 
Life Sciences, 201324. 
Other important players in the myogenesis pathway are the reactive oxygen species 
(ROS). ROS are oxygen-containing species that are chemically reactive and includes 
hydrogen peroxide (H2O2), superoxide (•O2
−) and hydroxyl radical (•OH). ROS origin can 
be mitochondrial, produced as waste when the electrons leaking from complex I and III 
react with oxygen, or cellular, generated by other cellular sources including NADPH 
oxidases, lipoxygenases, and cyclooxygenases with a different purpose like synthesis, 
signaling, or defense mechanism. ROS levels reduce the nuclear binding activity of the 
transcription factor AP-1, allowing the activation of the myogenin promoter for its 
expression. The activation of the satellite stem cells is mediated by mitogen-activated 
protein kinases (MAPKs) as a response to oxidative stress, inducing the expression of 
MyoD25. Lately, ROS have been found playing an important role as secondary 
messengers for many biological pathways such as healing process26, cancer metastasis27 
and accelerating the myogenesis28 
1.3. Skeletal muscle contraction 
The voluntary contraction of the skeletal muscle is induced by signals from the central 
nervous system29. A motor unit is formed by a motor neuron that goes from the spinal 
cord to the muscle fibers that innervates. The neuron transmits the action potential (AP) 
into the muscle fibers through the branches of its axon. The AP induces the secretion of 
the neurotransmitter acetylcholine (ACh) activating its receptors in the muscle fiber, 
causing the sarcolemma depolarization and generates a new AP. The AP spreads radially, 
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traveling into the cell via the T-tubes to reach the sarcoplasmic reticulum (SR) releasing 
the calcium contained inside into the cytoplasm. Calcium interacts with troponin changing 
its conformation and initiating the contraction. When the depolarization is over, calcium 
is reabsorbed by the SR through the SERCA (SR calcium-ATPase) pumps, and the 
contraction finishes leading to the relaxation of the muscle30. The myosin-actin cycling 
produces the contraction through the sliding of the actin and myosin filaments one over 
the other. This movement requires several steps and the hydrolysis of ATP as an energy 
source. In the first step, ATP binds the myosin’s head inducing its release from actin. In 
the next step, ATP hydrolyzes into ADP+Pi and the energy released induced the 
elongation of the myosin head and the binding in a new myosin-binding site in the actin. 
Finally, ADP+Pi is released and the head of the myosin bends producing the movement
31 
(Figure 5). 
 
Figure 5: Skeletal muscle contraction steps. Adapted from Earth’s Lab32. 
1.4. Fiber type and skeletal muscle function 
Muscle fibers are classified according to the myosin heavy chain (MHC) isoforms 
expressed on them. The MYH genes encode the expression of four MHC isoforms: MHCI 
(MYH7), MHCIIa (MYH2), MHCIIb (MYH4), MHCIIx (MYH1). MHCIIb is not 
expressed in humans limb muscles33, so only the other three MHC isoforms are present (I, 
IIa, and IIx). 
Muscle fibers are also classified depending on the speed of contraction (fast or slow) 
and the metabolism used for energy uptake (oxidative or glycolytic). The combination of 
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these two factors catalogs the muscle fibers according to differences in contraction, 
metabolism, and resistance to fatigue. Type I fibers have slow contractile speed and an 
oxidative metabolism thanks to a high mitochondria content, making them resistant to 
fatigue. Type II fibers are split into type IIa: fast with oxidative metabolism, type IIb: fast 
with a glycolytic metabolism, and therefore less resistance to fatigue and type 2X with an 
intermediate phenotype (Table. 1).  
 
Table 1. Fiber type classification in type 1 fibers (red) and type 2 (blue), according to the 
speed of contraction, metabolism, resistance to fatigue, and myosin isoform.  
The skeletal muscle fiber type composition is subordinated to the muscle functions. 
Usually, muscles are composed of different fiber types in diverse proportions, according 
to the need for contraction speed or resistance. However, the fiber type composition is not 
constant over individuals nor during life. Indeed, regular training changes the fiber 
composition with a positive effect on the speed or endurance of the specific muscle, on 
contrary, a complete fiber reorganization with loss in muscle properties is observed in 
muscle disuse or muscle diseases34. 
1.5. Myopathies 
Myopathies are clinical disorders of skeletal and cardiac muscles. Myopathies are 
classified as inherited, with a genetic component and an early age development, or 
acquired, with a sudden or subacute presentation at an older age. The manifestation of 
those diseases is usually in the form of weakness and muscle atrophy35.  
In this thesis within the inherited myopathies, we considered the hypertrophic 
cardiomyopathy (HCM) and protein aggregate myopathies (PAMs). HCM is a genetic 
condition that causes an increase in the wall thickness of the left ventricle, making it 
harder to pump the blood. It usually causes shortness of breath, chest pain, arrhythmias, or 
sudden death36. PAMs are a group of diseases of striated muscle with a very broad origin 
and cause misfolded proteins to aggregate, observed in pathologies like Alzheimer’s and 
Slow twitch
Fiber type Type 1 Type 2A Type 2X Type 2B
Speed of contraction Slow << Fast < Fast < Fast
Metabolic type Oxidative Oxidative Glycolytic Glycolytic
Resistance of fatigue High > High Low > Low
MHC gene MYH7 MYH2 MYH1 MYH4
Fast twitch
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Parkinson’s disease, epidermolytic keratin disease, or heart and skeletal muscle-like 
myopathy37. 
Among the acquired myopathies, Ventilator Induced Diaphragmatic Dysfunction 
(VIDD) and limb muscle inactivity were the ones used as muscle diseases models in this 
study plan. VIDD is the loss of diaphragmatic force-generating capacity caused by the use 
of mechanical ventilation. The outcome will cause difficulties in weaning from the 
ventilator and potentially the death of patients in the Intensive Care Unit (ICU)38. Limb 
muscle inactivity, associated with patients forced to rest due to injury or illness, has an 
atrophic effect in the muscle tissue since the body will break it down to conserve energy. 
Hyperglycemia is a severe condition associated with diabetes; a disease caused by the 
excess of glucose in the blood due to insulin-resistant problems. We adopted this 
pathological disorder to investigate how muscle regeneration is affected by high glucose 
conditions. Certainly, diabetes is usually associated with muscle mass loss due to the 
upregulation of factors like FOXO1 which trigger the skeletal muscle protein degradation 
pathways39.  
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2. SMALL UBIQUITIN-LIKE MODIFIER PROTEIN (SUMO) 
Protein post-translational modifications (PTM) are reactions catalyzed by enzymes 
where chemicals, lipids, sugars, or polypeptides are reversible or irreversible covalently 
attached to specific targets after their synthesis. These PTMs play an important role in 
dictating the target folding, function, localization, conformation, and activity. PTM are a 
fundamental part of the cellular and tissue signaling cascades that respond to intra and 
extracellular stimuli. A subgroup of PTMs showed the covalent linkage of small 
polypeptides, such as ubiquitin or ubiquitin-like molecules (UbLs, i.e., SUMO, NEDD8, 
ISG15, and ATG), providing a new structural reorganization of the target. This event 
possibly modulates the target-protein interactions, regulates the target activity, its 
subcellular localization, and stability or turnover. 
The Small Ubiquitin-like Modifier (SUMO) is a protein of 101-amino acids (11 kDa). 
SUMO is covalently attached to the lysine residues on target proteins via the 
SUMOylation enzymatic cascade reaction. Five SUMO mammalian paralogs, SUMO1 to 
SUMO5, are transiently and reversibly conjugated to the substrate (Figure 6).  
 
Figure 6: Alignment of amino acid sequences of SUMO5, SUMO1, SUMO2, SUMO3, 
and SUMO4. SUMO conjugation motifs are boxed by solid lines. The di-glycine motif 
for SUMO maturation is boxed by dashed lines. Yao Liang et al., Sci. Rep., 201640 
SUMO1, SUMO2, and SUMO 3 target a vast number of proteins for SUMOylation41. 
SUMO moieties are produced as precursors, and the isopeptidases, known as SUMO 
specific proteases, target them for its maturation42. Maturation generates a C-terminal 
carboxyl group, after a double glycine amino acid (SUMO-Gly-Gly-OH) that binds to the 
target protein lysine (K) residue in the consensus sequence, ΨKxD/E, via an isopeptide 
bond. In the consensus sequence, Ψ is a large hydrophobic residue, K is the target lysine 
and D/E are acidic residues43. SUMO2 and SUMO3 paralogs can polymerize, forming 
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polySUMO chains by covalent linkage of the C-terminal Gly-Gly-OH residue to a lysine 
available in their inner structure within a consensus sequence. SUMO1 lacks a consensus 
site and can’t produce poly chains, usually working as a mono SUMOylation link or 
terminator in a polySUMO2/3 chain. The study of SUMO4 functions is difficult due to its 
specific tissue distribution, but the presence of a proline residue in its sequence prevents 
its maturation and conjugation to proteins44. SUMO5, the last addition to the family 
seems to play a role in the disruption of promyelocytic leukemia nuclear bodies (PML-
NBs). SUMO5 helps to recruit components for its enlargement and enhance the 
conjugation of SUMO2/3 poly chains, inducing RNF4 activity for the PML-NBs 
disruption40. PML-NBs are interchromosomal accumulations of PML and other proteins 
that regulate diverse cellular processes like transcription, DNA repair, apoptosis, 
senescence, and tumor suppression. 
2.1. The SUMO cycle and SUMO enzymes 
SUMOylation is a dynamic reaction where only a small percentage of the targeted 
proteins is SUMOylated and their abundance is quickly affected as a response to internal 
or external cellular stimuli.  
During SUMOylation, SUMO is attached to the target proteins through an enzymatic 
cascade mediated by the hetero-dimer E1 SUMO-activating enzyme, SAE1/2, the E2 
SUMO-specific conjugating enzyme Ubc9, and in most cases, an E3 SUMO ligase, part 
of the PIAS enzyme family45 (Figure 7). 
The heterodimer of SAE1 and SAE2 triggers the activation of SUMO in an ATP-
dependent way and transfers it in the conserved catalytic cysteine of the conjugation 
enzyme Ubc9. Then Ubc9, up to date the only E2 identified, delivers the SUMO moiety 
to the substrates. In some cases, Ubc9 alone is sufficient for the conjugation and ligation, 
however, the presence of the SUMO E3 ligases, facilitate the interaction of Ubc9 with the 
substrates, direct Ubc9 to specific targets, promote polySUMO chain formation, and 
introduce additional SUMO acceptor sites46,47 (Figure 8). 
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Fig. 7: Mechanism of SUMOylation. SUMO cycle with consecutive steps for the SUMO 
conjugation/deconjugation into the target (A). Different SUMO conjugation options with 
SUMO1 and SUMO2/3, from single units to poly chains (B). Andrea Rabellino et al., 
Cancer Res, 201748. 
 
Fig. 8: PIAS proteins structure. SAP (DNA-binding motif), PINIT (nuclear translocation) 
RING (E3 SUMO protein ligase), ADSIM (acidic domain-containing SIM), S/T rich 
(Serine/threonine-rich C-terminal). Andrea Rabellino et al., Cancer Res, 201748. 
In the case of SUMO, the covalent enzymatic reaction is reversible and mediated by 
specific proteases. In humans, three families are involved to assess the SUMO 
deconjugation and they are classified as SENPs42, Desi49, and USPL150. These enzymes 
show specific activity among the different SUMO paralogues and different localization in 
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the cellular and nuclear compartments. SENPs contain a specific N-terminal domain in 
charge of the regulation of the cellular localization, proposing that each SENP may have a 
specific group of substrates51 (Figure 9).  
 
Figure 9: Structures of SUMO proteases. SUMO specific proteases with corresponding 
domains: catalytic domain in magenta, regions for intracellular localization in cyan, and 
SIM domains marked with asterisks. Christopher M. Hickey et al., Nature Reviews 
Molecular Cell Biology, 201252. 
Besides SUMO conjugation into proteins, non-covalent protein interaction with 
SUMO is possible through the SUMO interaction motifs (SIMs). SIM domains contain a 
Val/Ile-X-Val/Ile-Val/Ile sequence that allows SUMO binding53. 
A connection between SUMO and Ubiquitin pathways was discovered with the 
SUMO-targeted ubiquitin ligases (STUbLs). STUbLs bind poly-SUMO2/3 chains via 
SUMO interaction motifs (SIMs) in tandem and target the SUMOylated protein with 
ubiquitin chains for degradation through the proteasome system. One example of this 
protein family is the mammalian RNF4, involved in the ubiquitin-dependent degradation 
of promyelocytic leukemia bodies (PML) after poly-SUMO2/3 conjugation, induced by 
different types of cellular stress54. The minimum amount of SIMs required to bind poly-
SUMO chains is two, as it was demonstrated by the mutation of the different SIM 
domains in RNF4 sequence55.  
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2.2. SUMOylation regulates diverse biological processes 
SUMOylation is an important PTM involved in the regulation of crucial cellular 
functions including developmental and differentiation, and its alteration contributes to 
severe human diseases. However, most of the studies were performed on single 
eukaryotic cells from yeast to primary cells. The involvement of SUMOylation in 
regulating activity, functions, development, and disorders in complex systems like 
differentiated tissues (i.e., brain and muscles) is just emerging.  
The SUMO network is vital for the survival of eukaryotic cells and changes in the 
expression levels of one enzymatic component may destabilize the entire cell behavior. 
For example, low levels of SAE1/2 will reduce the aggressivity of breast cancers with 
high expression of Myc56, but in mammalian cells and mice embryos in development, the 
deletion of the SUMO E1 enzyme has a lethal efffect56,57. The high abundance of Ubc9 
observed in the hippocampus and cerebral cortex suggests a potential role of 
SUMOylation in the synaptic and neuronal plasticity58, but overexpression of Ubc9 is 
observed in ovarian, hepatocellular, prostate, and lung carcinomas59. 
The SUMO enzymes regulate the coupling and uncoupling of the SUMO moieties on 
the targeted protein in a balanced manner, as it has been observed in the cardiac gene 
regulation for the development and maintenance of the normal cardiovascular system60. 
Indeed, different abundances of SUMO enzymes were notified and associated with an 
altered SUMO reaction equilibrium, with a consequent variation in the total SUMOylated 
protein profiles observed, for example, in heart biopsies of patients who had severe 
developmental heart defects, including cleft lip and cardiac malformation61. 
The equilibrium of the SUMOylation reaction is also altered under different stress 
conditions including heat shock, high oxidative or osmotic environments, and ethanol 
poisoning. Stress situations are usually associated with a large increase in the global 
SUMOylation by SUMO2/3 in mammals, plants, and yeast62. Although this increase of 
SUMOylation is widespread in these situations, the affected substrates and regulatory 
circuits remain, however, largely unknown. 
SUMO conjugation triggers the targeted protein in three different aspects: alters the 
activities, consents the localization or relocation in different cellular districts, or facilitates 
the interaction with other proteins. In fact, RIM1α, the Rab3-interacting molecule 1α, 
involved in the neuronal function, requires the conjugation with SUMO1 to increase the 
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synaptic vesicle presynaptic exocytosis activity63 and the protein interaction of RanGAP1, 
(GTPase-activating protein for Ran that regulates the cytoplasm-nucleus transport), with 
the nuclear pore complex protein RanBP2 (RAN binding protein 2) and its nuclear 
translocation is allowed only when the first one is SUMOylated64. 
2.3. SUMO implication in skeletal muscle pathophysiology 
The complexity of skeletal muscle physiology requires a crucial regulation and 
coordination of diverse muscle activities. As a new integrator pathway, SUMO 
orchestrates the correct functions of different cellular networks as they are summarized 
below. 
SENP1 and SENP2 are important SUMO deconjugases operating in the myogenesis 
process65,66. As an example, the deSUMOylation of Sharp-1 mediated by SENP1, inhibits 
its activity, while SENP2 cleaves SUMO moieties from the transcription factor Mef2A, 
and promotes the skeletal muscle differentiation.  
The sarcomeric organization is coordinated by the SUMOylation of different 
components like the Mef2 family of transcription factors67, which enhances the 
transcription of Myomesin-1 for its incorporation into the sarcomeric structures68. 
Proteins involved in the mitochondrial adaptation to exercise like the myocyte enhancer 
factor-2 (Mef2), the peroxisome proliferator-activated receptor-gamma coactivator 1 α 
(PGC1α)69, p38, and c-Jun70, need the SUMO conjugation for its nuclear translocation. 
The control of muscle energy metabolism is critical to avoid the development of 
metabolic syndromes or to correct obesity disorders. The inhibition of the Krüppel-like 
transcription factor 5 (KLF5) by SUMO attachment blocks its activity regulating the lipid 
metabolism71. Overexpression of Ubc9 protects the glucose transporter GLUT4 from 
degradation and increasing the response to insulin in adipocytes72.  
SERCA, the sarco/endoplasmic reticulum Ca2+-ATPase has the role of transferring 
calcium from the sarcoplasm to the SR lume during muscle relaxation. SERCA2a is the 
isoform expressed in cardiac muscle and slow-twitch skeletal muscle. The conjugation of 
SUMO1 in SERCA2a has a protective effect during heart failure, with the increase of 
SUMO1 levels restoring SERCA2a levels73. 
There are some animal models developed to study the role of SUMO in different 
pathologies. SENP1 knockout or flox inducible for the study of apoptotic death during 
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transient brain ischemia/reperfusion74 or His6-HA-SUMO1 KI mice for brain analysis of 
SUMOylated proteins75. 
2.4. SUMO as drug targetable pathway 
A new line of research has emerged looking for compounds with effects in the 
modulation of SUMO PTM related to human diseases. New drugs are also designed to 
affect the main properties of the enzymes involved in the SUMOylation process to 
improve or reduce the interaction and/or conjugation of specific SUMO substrates. The 
massive changes in SUMO components associated with cancer, cardiac, and 
neurodegenerative diseases76 give an insight into how important it is to keep a well-
balanced SUMOylation profile. The peculiar reversible conjugation characteristic of 
SUMO makes it perfect for the development of specific pharmacological drugs to revert 
the effect of pathologies through its modification. In the last years, new drugs are starting 
to be established and to prove its positive effects in the treatment of heart failure, cancer, 
and other pathologies. 
In vivo and in vitro studies provided new results showing the inhibitory effect of some 
drugs over the E1 activating enzymes SAE1 and SAE2. The gingkolic and anacardic 
acids impair the formation of the E1-SUMO intermediate77 and show a positive effect in 
the treatment of non-promyelocytic leukemias78. A similar effect over the formation of the 
E1-SUMO intermediate was observed using kerriamycin B79 and davidiin, having the last 
one a more potent effect even in lower doses80. The only drug under clinical trials right 
now is the inhibitor TAK-981, with an effect blocking the SUMO transference between 
the E1 and Ubc981. 
On the contrary, the use of the small molecule N106 enhances the binding interaction 
of both E1 subunits, SAE1 and SAE2 increasing its conjugation activity and the 
SUMOylated fraction of SERCA2a, as a potential therapeutic strategy for heart failure 
treatment82. 
Ubc9 is also a drug target. Spectomycin B1 binds Ubc9 inhibiting its activity83, and 2-
Do8 blocks the SUMO transfer from the E2 to the substrate84. 
Topotecan decreases the total SUMOylation levels in glioblastoma cells by impairing 
SUMO1 conjugation of CDK6 and causing its degradation, but unfortunately, the 
mechanism involved in this activity is yet to be discover85. 
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Finally, several new protein-based inhibitors and activity-based probes are useful for 
the inhibition of the SUMO deconjugases (SENPs) due to its implication in several 
cancer86 (Figure 10).  
 
Figure 10: Overview of inhibitors and probes of SENPs. List of SENPs inhibitors and 
probes. Jia Yuqing, ACS Chemical Biology, 201986.   
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3. UBIQUITIN AND THE UBIQUITIN-PROTEASOME SYSTEM 
Goldstein discovered the ubiquitin-protein in 197587. Ubiquitin is a 76-amino acid 
peptide (9 kDa) and is covalently attached to the target through the ubiquitin cycle. The 
studies of the ubiquitin-mediated proteasomal degradation of regulatory proteins showed 
the essential role of the ubiquitin cycle in the cells. Ubiquitination controls many 
processes, including cell-cycle progression (cyclins and Cdk), signal transduction, 
transcriptional regulation (tumor suppressors, proto-oncogenes), receptor down-
regulation, immune response, development, apoptosis, and endocytosis88. Pathological 
conditions, including malignant cell transformation, emerge when the ubiquitin pathway 
suffer alterations. 
Ciechanover and Hershko found in 1978 that the ubiquitin-mediated proteolysis 
required the use of ATP as an energy source89. Ubiquitin is attached to the target protein 
through the sequential action of three enzymes. First, a specific activating enzyme (E1) 
activates the ubiquitin C-terminal Gly residue with ATP energy consumption. Through 
this step, an intermediate ubiquitin adenylate is created, PPi released and ubiquitin binds 
to a Cys residue of E1 in a thioester linkage, with AMP release. After that, the activated 
ubiquitin is transferred to a Cys active residue of a ubiquitin-carrier protein (E2) and 
finally a ubiquitin-protein ligase enzyme (E3) catalyzes the ubiquitin union in the 
substrate lysine residue by its C-terminus90,91. Once one ubiquitin molecule is attached to 
the protein, the process is repeated several times to form a polyubiquitin chain. 
Ubiquitin has several lysines in its sequence helping to create different types of 
ubiquitin chains with specific functions. Lys48 ubiquitin poly chains mainly target 
substrates for the proteasome degradation, but new functions like the activity regulation of 
the transcription factor Met4 or the ubiquitin selective chaperone p97 activation are also 
performed92. Chains form through the Lys63 have non-proteolytic functions in different 
pathways including DNA damage repair, cellular signaling, intracellular trafficking, and 
ribosomal biogenesis, but new studies show its involvement in the degradation of some 
targets93. Unconventional ubiquitin poly chains of Lys6, Lys27, Lys29, and Lys33 have 
been found, but their function remains unknown. 
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3.1. Ubiquitinating enzymes 
The E1 ubiquitin-activating enzymes catalyze the first step in the ubiquitination 
reaction94. The human genome encodes two E1 for the ubiquitin pathway: 
UBA1 contains four different domains for the interaction with ATP95 and Ub, the 
active cysteine, and the recruitment of specific E2s96. 
UBA6: Shares 40% of its sequence with UBE1 and some E2s, but it also has specific 
E297. 
The E2 ubiquitin-conjugating enzymes participate in the protein substrate recognition, 
either alone or in combination with an E3 enzyme, being able of great specificity or 
overlapped functions. The E2-E3 interaction is very complex, involving different levels of 
specificity with a very precise effect over the target. 
E3 enzymes are classified into three types of ubiquitin-protein ligases: HECT, U-box, 
and RING-finger. They have an important role in the specific bind of the E2 to the 
substrate and up to date, 500-1000 E3 ligases are described98. These enzymes localize in 
the different organs with tissue specificity and different localization in the cellular 
compartments, demonstrating how critical specificity is for the ubiquitin pathway. 
3.2. Deubiquitinating enzymes 
Before the ubiquitinated protein goes inside of the proteasome for degradation, the 
ubiquitin polychain is removed. Six families of enzymes are the ones performing the task: 
ubiquitin-specific proteases (USPs), ubiquitin C-terminal hydrolases (UCHs), Machado-
Josephin domain proteases (MJDs), ovarian tumor proteases (OTU), Jab1/Mov34/Mpr1 
Pad1 N-terminal+ (MPN+) (JAMM), and the ZUFSP. USPs detach ubiquitin from the 
poly-ubiquitinated proteins, UCHs cleaves Ub/NEDD8, target ubiquitin precursors for 
maturation, and interact with Lys48 Ub chains to protect them from degradation. MJDs 
and OTU have high Ub chain specificity (K11, K48, K63) with specific roles99. JAMM 
are the only metalloproteases and use Zn+ in its active site for the deubiquitination100. 
ZUFSP has a single protein in the family, ZUP1 with an important role in genome 
stability. 
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3.3. E3 ubiquitin ligase MuRF1 
MuRF1, MuRF2, MuRF3 compose the C-II family of TRIM proteins and are only 
expressed in cardiac, skeletal, and smooth muscles. All three proteins can homo- and 
hetero-dimerize via their coil domains. MuRF1 is a protein of 353 amino acids (40 kDa) 
encoded by the TRIM63 gene, MuRF2 (51 kDa) by TRIM55 and MuRF3 (40 kDa) by 
TRIM54 (Figure 11). 
  
Figure 11: MuRF domains. MuRF protein family with corresponding domains. RING, 
MFC (MuRF family-specific domain), BB (B-box), helical region (coiled-coil domain), 
COS (C-terminal subgroup One Signature-box), and AT (acidic tail). Dr. Benjamin 
Suenkel, The Max Delbrück Center for Molecular Medicine101. 
Like the other TRIM proteins, MuRF1 follows the domain pattern of a RING-finger 
domain (E3 ubiquitin ligase function), followed by an MFC, a highly conserved region in 
the MuRF family for binding to PPAR (peroxisome proliferator-activated receptors). A B-
box and two coiled-coil domains (helical region and COS) localize after them, for protein 
interactions and microtubule-binding, with an acidic tail at the end of the sequence that 
promotes binding with the microtubules with the help of the coiled-coil domains102. 
MuRF1 was first identified as a novel muscle-specific RING finger protein that bound 
to the kinase domain of the giant sarcomeric protein titin. MuRF1 localize at the M- and 
Z-line of the sarcomere103 associated with MuRF2 and MuRF3. When there is inactivity, 
unloading, or muscle stress conditions MuRF1 is translocated into the myonucleus, where 
it may influence gene expression in the different atrophy models. The specific role could 
be direct, acting as a transcription factor or indirect, mediating polyubiquitin degradation 
of other transcription factors104. 
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MuRF1 is the only family member related to muscle atrophy because its transcription 
is under the control of FOXO1 and FOXO3a that increases during certain forms of 
atrophy. The two major classes of proteins as putative substrates for MuRF1 are 
myofibrillar proteins and proteins occupied in ATP generation, in particular those 
involved in glycolysis, suggesting that MuRF1 could have a role in metabolic regulation 
since it was observed in cardiac mitochondria reducing the reactive oxygen species 
levels105. 
3.4. SUMO pathway and Ubiquitin Proteasome System 
Ubiquitin and SUMO are part of the same family of ubiquitin-like proteins and 
common elements are shared in both pathways. They use similar enzymatic reactions 
involving the E1 activating, E2 conjugating, E3 ligase, and deconjugases enzymes to 
regulate the SUMO and Ub binding to the substrate’s lysine. On the contrary, there are 
also some differences between the two pathways, SUMO enzymes cannot work as 
Ubiquitin-conjugating and deconjugating enzymes, and vice versa. More, predominantly, 
the main task described for the ubiquitin conjugation is the proteasomal degradation of 
proteins in the different cell compartments106,107, while the SUMO moieties conjugation 
affects the enzymatic activity, protein-protein interactions, and cellular localization of the 
targeted proteins.  
A large pool of proteins is a substrate for both SUMO and ubiquitin. Since both cycles 
usually compete for the same lysine, the expected result is an antagonistic effect108. 
Interestingly, a cooperative effect is observed in SUMO2/3 chains conjugated to specific 
substrates, which become a target of polyubiquitination reaction, mediated by the SUMO-
targeted ubiquitin ligase (STUbL), RNF4, and addressed for proteasomal degradation109. 
Both ubiquitin and SUMO pathways can cross-regulate each other through the 
modification of their components, for example, the inhibition by SUMOylation of the 
ubiquitin E2-25k110, the Gam1 ubiquitination of SAE1 for its degradation111 or the 
complex relationship between the ubiquitin E3 enzyme Parkin and the SUMO E3 
RanBP2. Parkin ubiquitinates RanBP2, promoting its degradation and RanBP2 binds non-
covalently to Parkin enhancing its activity112. 
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3.5. The ubiquitin and UbLs family 
Besides Ub and SUMO previously mentioned, the ubiquitin-like protein family is 
formed by other proteins with similar structure but involved in the regulation of different 
cellular processes in the nuclear transport, proteolysis, translation, autophagy, and 
antiviral pathways113 (Figure 12). 
  
Figure 12: Schematic overview of the enzymatic cascades involved in the Ub and UbL 
conjugation pathways. Ubiquitin and ubiquitin-like family of proteins with 3D structure. 
Conjugation cycle with corresponding enzymes and known substrates for each UbL. 
Martine Biard-Piechaczyk et al. Biology of the Cell, 2012114. 
Nedd8 has a 58% similarity to Ub and was first found as one of the ”Neural precursor 
cell-Expressed, Developmentally Downregulated” genes expressed in embryonic mouse 
brain. Nedd8 regulates the Cul family members, needed for the assembly of 
multicomponent RING E3 ligases. 
FAT10, the HLA-F adjacent transcript 10, is expressed in dendritic and B cells 
cytoplasm and is involved in the immune response, induction of caspase-dependent 
apoptosis, NF-κB activation, cell-cycle defects, and chromosomal instability. 
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ISG15, interferon-stimulated gene 15, was the first UbL identified and is involved in 
the interferon signaling after infection. Interferon type I mediates its expression and acts 
targeting viral and host proteins. 
Atg8/LC3 and Atg12 regulate autophagosomal membrane growth and expansion: 
There is a correlation of Atg8 levels and the size of the autophagosomes, Atg12 forms a 
complex with Atg5 and Atg16L1 and works as an E3 ligase in the external side of the 
autophagosomal membrane.  
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4. AIMS OF THESIS  
This thesis aims to understand the role played by the SUMO post-translational 
modification in the pathophysiology of skeletal muscle. We hypothesize that an 
invaluable role as a cellular sensor of environmental changes is attributed to the SUMO 
pathway for the correct muscle performance. Thus, by associating the alterations of the 
SUMO network with muscular diseases, we provide a new angle to understand the origins 
and offer potential innovative treatments for severe muscle pathologies.  
4.1. Specific aims: 
- To understand the functions of SUMOylation in the skeletal muscle 
physiology. Study the adaptation of the SUMO pathway under altered muscle 
conditions.  
 
- To characterize the SUMO PTM on the E3 Ubiquitin ligase MuRF1. 
Understand how SUMOylation influences MuRF1 activity and cellular localization. 
Associate MuRF1-related human muscular disorders to its alterations in SUMO 
conjugation. 
 
- To associate an unusual distribution in the SUMO enzymes and the 
SUMOylated proteins to the skeletal muscles localized in different body districts. 
Study the implications of the SUMO network modulation in muscle adaptation. 
 
- To determine the variations of SUMO PTM in the myogenesis processes. 
Associate the impairment of muscle regeneration under hyperglycemic conditions 
with alterations in the SUMOylation reaction events during the myogenesis process.  
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5. METHODOLOGICAL CONSIDERATIONS  
5.1. Eukaryotic cell lines  
Immortalized murine myocytes, C2C12, and HeLa cells were cultured in DMEM-
normal glucose (5.5 mM, 308-340 mOs/Kg) or high glucose (25 mM, 313-346 mOs/Kg) 
media, supplemented with 10% FBS and 100 IU/ml of penicillin-streptomycin antibiotics. 
Cells were grown in a humidified air atmosphere at 37 °C in presence of 5% CO2.  
5.2. Rodents and human samples  
Rats: Female Sprague-Dawley rats were deeply sedated by isoflurane inhalation, 
paralyzed with α-cobratoxin, and maintained in constant protein, and fluid balanced from 
the beginning to the end of all mechanical ventilation processes. Animals were monitored 
continuously to detect any pain reactions (EEG activity, heart rate, and intra-arterial blood 
pressure). For the pharmacological assay, rats were treated with BGP-15 drug (40 mg/kg 
dose) during the desired period of mechanical ventilation. Control rats, not subjected to 
mechanical ventilation, were anesthetized with isoflurane for two hours and then 
euthanized. The experimental procedure was ended at different time points, from few 
hours to 2 weeks of mechanical ventilation, and animals were sacrificed by thoracotomy, 
hearts were removed, and all tissues were harvested. Surgery was performed under sterile 
conditions. All necessary steps were taken to minimize animal suffering described in the 
ethical permit N263/14.  
Wistar-Han rats were caged individually and randomly assigned to experimental 
groups: freely ambulating as controls, 1-, 2-, and 4-days hind limb-unloaded animals. 
Hind limb muscles were unloaded using the tail suspension rat model, by wrapping the 
tail root with tape under general anesthesia, induced with intraperitoneal administration of 
20 mg/kg of zolazepam chlorhydrate and tiletamine chlorhydrate. All animals were 
euthanized in the presence of anesthesia with isoflurane according to the ethical permit 
502/2015-PR. Limb muscles were excised and frozen in liquid nitrogen.  
Mice: BKS Cg-Dock7m+/+ Leprdb/J male mice, were used as a model of chronic 
hyperglycemia, this strain is used as a model in phases I - III of diabetes type II and 
obesity. 8- to 10-week-old mice were sacrificed by cervical dislocation and the respiratory 
muscles were immediately isolated and deeply frozen in liquid nitrogen and storage at 
−140°C. 
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Human: Muscle biopsies were isolated from the vastus lateralis muscle of volunteers 
participating in a campaign of muscle inactivity performance at 0, 8, and 35 days after a 
bed rest period. Procedures were described in the ethical permit 502/2015-PR. 
5.3. ORFs cloning in expression vectors 
To clone the ORFs of the analyzed proteins in prokaryotic and in eukaryotic plasmids, 
cDNAs generated from rodents or human skeletal muscle RNAs were used as templates 
and PCRs were performed together with designed primers containing specific restriction 
sites for the cloning. The PCR reactions were performed with 40 ng template, 20 μM 
forward and reverse primers, 20 mM dNTP’s mix, High Fidelity Buffer, and 2 U Pfu 
enzyme in a final volume of 50 μl. The PCR cycling program was: denaturation 95°C for 
5 min, followed by 25 cycles of denaturation 95°C for 30 sec, annealing (temperature 
according to the primers TM) for 30-60 sec, polymerization 72°C for 1 min, and a final 
step of 72°C for 10 min elongation. Amplicons were purified in agarose gel and extracted 
by using a gel extraction kit following the manufacture instructions. Ligase reactions were 
performed combining the digested plasmids and amplicons (molar ratio 1:3) in presence 
of ligase enzyme with the appropriate buffer, for 16 h at room temperature. Ligase 
reactions were used to transform competent DH5α and plated on bacteria LB agar 
medium, supplied with the appropriate antibiotic selection. Colonies were visible after 24 
h of incubation at 37°C. 
5.4. Side direct mutagenesis 
The site direct mutagenesis was performed on the ORFs nucleotide sequences to 
generate proteins with different amino acid sequences. For this purpose, the QuikChange 
II Site-Directed Mutagenesis kit was adopted and complementary primers including the 
desiderated mutations were designed for each case. The mutagenesis reaction contained 
100 ng of plasmid template, 20 μM of primers, 20 mM of dNTP’s mix, High Fidelity 
Buffer, 2 U of Pfu Taq DNA polymerase, in a total volume of 50 μl. When required, 8% 
DMSO was added to the final reaction. The cycling program was: denaturation 95°C for 3 
min, followed by 16 cycles of 95°C for 30 sec, 65°C for 1 min, 72°C for 5 min with a 
final step of 72°C for 10 min. After PCR, samples were treated with the DpnI enzyme at 
37°C for 1 h in the presence of the appropriated reaction buffer. 20 μl of the digested 
sample was used to transform 50 μl of DH5α competent bacteria and plated on bacteria 
LB agar medium, supplied with the appropriate antibiotic selection. Colonies were visible 
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after 24 h of incubation at 37°C. Colonies were grown in the appropriated media 
overnight and the plasmid DNAs were extracted using Mini-Prep commercial kit, 
quantify and send to the sequence to confirm the nucleotide mutations. 
5.5. Eukaryotic cells transfection 
Exponential C2C12 and HeLa cells were transfected with the desired plasmids using 
lipofectamine probes according to the manufacturer’s protocol.  
5.6. Cells and muscle lysates  
Cells were lysed with RIPA buffer (25 mM Tris-Cl pH 7.5, 50 mM NaCl, 0.5% NP40, 
1 mM EDTA pH 8.5, 1 mM DTT, 20 mM NEM, protease inhibitors) and passed 2–3 
times through a syringe provided with a G28 needle to disrupt genomic DNA. Crude 
lysates were clarified with centrifugation for 15 min at 10000 g, 4°C, and protein 
concentration was measured with BIORAD protein assay kit using BSA standard curve. 
Frozen muscle biopsies were incubated with lysis buffer (50 mM Tris-Cl pH 7.4, 150 
mM NaCl, 1 mM EDTA, 1% SDS, 0.5% DOC, 0.5% NP40, 1 mM DTT, 10 mM NEM, 
20 mM Iodoacetamide, fresh protease inhibitors cocktail) for 15 min on ice, then 
homogenized in a 1.5-ml tube with pestle. Muscle homogenizes were centrifuged for 20 
min at 10000 g, 4°C. Clear supernatants were collected and protein concentrations were 
measured with the BIORAD protein assay kit using BSA standard curve. 
5.7. Immunoblotting  
Desired amounts of sample lysates were resuspended in loading buffer and denatured 
for 10 minutes at 95°C, loaded and fractionated in acrylamide Bis-Tris 4%-12% gradient 
gels. Proteins were transferred onto PVDF membrane for 60 minutes at 0.34 A, and 
blocked in TBS (50 mM Tris-Cl, 150 mM NaCl, pH 7.6) containing 0.1% Tween-20% 
and 5% skimmed milk. Membranes were incubated with the specific primary antibodies 
overnight at 4°C, followed by a 1-hour incubation with the appropriate horseradish 
peroxidase-conjugated secondary antibodies. The immunocomplexes were visualized by 
chemiluminescence and detected by ChemiDoc MP Imaging System. Band signals were 
acquired and analyzed with the correspondent imaging analysis software, version 5.0. 
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5.8. Quantitative real-time PCR  
Gene transcripts were assayed by qPCR using specific primers designed with 
PRIMER3 software. RNAs extraction was performed following the manual instructions 
included in the GeneJET RNA purification kit. Extracted RNAs were purified from 
genomic DNA contamination with DNase I/RNAse-free treatment. The correspondent 
cDNAs were produced using oligo (dT)18 and random primers by following the 
instruction of RevertAID H Minus First-strand cDNA synthesis kit. qPCR reactions were 
performed with 100 ng of cDNA template, in presence of the specific primers and SYBR 
Green Master Mix, in a 20 μL of the final volume. The analysis was performed with 
QuantStudio 3 Real-Time PCR Systems instrument, with the following cycling program: 
initial at 50°C for 2 minutes, denaturation at 95°C for 10 minutes, followed by 40 cycles 
at 95°C for 15 seconds, and at 60°C for 1 minute. A final step of “melting curve” cycle 
between 65°C and 90°C, 1°C/s temperature speed was incorporated. Fold change relative 
to a housekeeping control gene (gapdh) was calculated as 2−ΔCt where: 
ΔCt=Ct(target)−Ct(gapdh), according to the Minimum Information for Publication of 
Quantitative Real-Time PCR Experiments (MIQE) guideline. To calculate relative gene 
expression levels between differently treated samples, 2-ΔΔCT was used to determine fold 
transcript changes, where ΔΔCt=ΔCt(target gene after treatment)−ΔCt(target gene before 
treatment). All samples were analyzed in triplicate and mean and ± SD were obtained. 
5.9. Protein purification 
Prokaryotic cells: E. coli BL21 bacteria were transformed with the desired plasmids 
and colonies were selected within the appropriate LB agar medium. After exponential 
growth, IPTG-protein induction was performed. Bacteria were collected and lysed. The 
proteins of interest were purified using the different methods according to the specific 
conjugated tag. Purified proteins were either separated by SDS-PAGE gel and stained 
with Coomassie blue or directly used for enzymatic assays.  
Eukaryotic cells: Cells were harvested using cold PBS, when necessary in presence of 
0.2 M iodoacetamide, and lysed with specific lysis buffers. Lysates were centrifuged at 
for 10 min, 10000 g, at 4°C. Native or overexpressed-tagged proteins were purified using 
the specific antibodies conjugated to sepharose beads or with commercial tag-trap 
columns, following the manufacture´s purification protocols.  
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Muscles: Approximately 200 mg of muscles tissue were lysed in an optimized lysis 
buffer (Tris-Cl 150 mM, NaCl 150 mM, SDS 0.5%, NP-40 1%, DOC 0.5%, EDTA 5 
mM, DTT 1 mM, fresh NEM 20 mM, and protease inhibitors, pH 7.6). Muscle lysates 
were precleared with protein G-agarose beads coupled to anti-normal mouse IgG for 3 h 
and gently rotated at 4 °C before the incubation with protein G-agarose beads coupled to 
specific antibodies. Beads were collected by centrifugation and washed twice with PBS 
containing 0.01% NP40. Immunocomplexes were eluted by competition with specific 
peptides. Elutes were used for mass spectrometry analysis or protein-protein interaction 
assays. 
5.10. Immunocytochemistry 
C2C12 cells were seeded in 13-mm diameter coverslips precoated with poly-D-lysine 
in 12-well plates. When required, exponential cells were transfected with plasmids for 
protein expression assays or differentiated into myotubes with an appropriate medium. 
Coverslips were washed three times with cold PBS and fixed with filtered 4% 
paraformaldehyde dissolved in PBS, for 20 min at RT. Fixed cells were permeabilized 
with 0.5% Triton-X100 for 1 h at RT. 3% BSA in PBS was used as a blocking solution 
and slides were incubated for 30 min at RT. After that, 1 h incubation with primary 
antibodies, three PBS-washed, and 1 h incubation with the secondary antibody were 
performed. Coverslips were transferred on an objective glass with a mounting solution 
containing DAPI probe to stain nuclei. Confocal or fluorescent microscopes were used to 
acquire the images. 
5.11. Immunohistochemistry 
Frozen muscle biopsies were fixed with Compound for Cryostat Sectioning (OCT) 
and cryosectioned into 10 μm slices at −20°C. Cryosections were incubated at room 
temperature (RT) for 5 min, rehydrated in PBS for 15 min at RT, fixed in cold acetone at 
−20°C for 15 minutes, dried for 1 minute at RT, and blocked with 3% BSA in PBS for 40 
minutes at RT. Incubation with primary antibodies was performed for 90 minutes at RT, 
then washed 3 times for 5 minutes with PBS, followed by a 1-hour incubation with 
secondary antibodies and washed again with PBS. The slides were mounted with 
Fluoroshield medium containing DAPI. Pictures were acquired using a ZEISS laser 
scanning confocal microscope using a fixed protocol for all sections. 
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5.12. ATPase pH 10.4 staining 
Cryosections were incubated with alkaline solution 1 (0.1 M Glycine, 5.4 mM CaCl2, 
0.1 M NaCl, pH 10.4 adjusted with 0.1 M NaOH) for 9 min at 37°C. Then, washed with 
water, and incubated with solution 2 (17 mg Na2ATP in 10 ml of Solution 1, pH 9.4 
adjusted with HCl) for 30 min at 37°C. Samples were washed and incubated 
consecutively with 1% CaCl2 for 3 min at RT, 2% CoCl2 for 3 min, 1% (NH4)2S for 1 min 
at RT, with washes performed between the different incubations. Finally, slides were 
mounted in glycerine gelatin. Pictures of staining were acquired using Nikon Phase 
Contrast 0.90 dry microscope. 
5.13. NADH-TR staining 
Cryosections were incubated in 30 ml of NADH-TR solution (28 mg Nitroblue 
Tetrazolium, 6.25 ml 0.1 M MOPS solution pH 7.4, 10 mg Nicotinamide adenine 
dinucleotide in 30 ml H2O) for 20 min at 37°C. Then the sections were washed with 
running distilled water to remove any excess NADH-TR solution on glass slides. Sections 
were kept for drying at RT for 15 min and cover glass was mounted with glycerine 
gelatin. Pictures of staining were acquired using Nikon Phase Contrast 0.90 dry 
microscope. 
5.14. Images processing software 
ImageJ software was used as a processing program to quantify band intensity from 
western blots, and fluorescences from immunofluorescence muscle section pictures.  
5.15. ROS detection 
Exponential C2C12 cells and derived myotubes cultured in medium containing 
different amounts of glucose with and without ROS inhibitors, or overexpressing specific 
proteins, were seeded in 24/96-well plates. Intracellular and mitochondrial ROS were 
measured using commercial kits following the manufacturer’s protocol.  
5.16. Myogenesis 
Confluent C2C12 cells were differentiated in myotubes using differentiation medium 
(DMEM + 2% horse serum). Fresh medium was supplied to the culture every two days 
during differentiation to provide a constant amount of glucose. When required, 10 μM 
anacardic acid or 2 μM topotecan were added as indicated. These drug concentrations 
were selected based on C2C12 and myotubes toxicity tests performed previously. Stocks 
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were prepared in DMSO and the final working concentration did not exceed 0.01% v/v, 
resulting in no DMSO-induced cellular cytotoxicity or alteration of the myogenesis 
process. All four myogenesis processes (NG, HG, HG+anacardic acid, and 
HG+topotecan) were performed in parallel. 
5.17. Cellular senescence assay 
C2C12 cells were cultured and myogenesis was induced in media. β-galactosidase 
assays were performed with the senescence cells histochemical staining kit according to 
the manufacturer’s protocol. 
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6. RESULTS AND CONCLUSIONS 
6.1. Paper I 
A well-maintained muscle is very important for the activities of daily life. The good 
status of the muscle is conserved by intricated and interconnected pathways able to 
quickly adapt to different situations. Our hypothesis was to understand how SUMOylation 
collaborated in the correct skeletal muscle functions under normal activity, and how it 
responded in cases of skeletal muscle diseases.  
To achieve the results, we analyzed diaphragm muscles from ambulatory rats as 
control, and under controlled mechanical ventilation (CMV) as an acquired muscle 
disease model. Indeed, prolonged exposure to CMV treatment results in the development 
of Ventilator-Induced Diaphragm Dysfunction (VIDD). VIDD is a common disease in 
ICU patients that causes a delay in the weaning from intubation due to diaphragm 
weakness and affects the quality life of the patients115. 
6.1.1.  SUMOylated proteins are unevenly distributed in the muscle fibers 
The distribution of SUMO conjugated proteins in the different muscle fibers is 
unknown. To investigate this, we performed consecutive diaphragm cryosectioning from 
control rats and immunostained the sections either with SUMO1 or SUMO2/3 antibodies 
or with fiber type identifier markers NADH-TR (to identify oxidative or glycolytic fibers) 
or myosin ATPase (to identify myosin type I or II fibers) (Figure 13). 
 
Figure 13: Immunofluorescence analysis of SUMO conjugates in the control diaphragm. 
Muscle fibers stained with antibodies to SUMO1 (a) and SUMO2/3 (d). White boxes are 
enlarged, showing the nuclear localization of both SUMO1 and SUMO2/3 (b and e). 
Consecutive serial muscle sections were subjected to NADH-TR staining to recognize the 
oxidative (O, dark purple) and glycolytic (G, light purple) fibers (c and f). Scale bars, 50 
µm (panels a–d and c–f), and 20 µm (panels b–e). 
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The results obtained surprisingly showed a mosaic-like distribution of SUMOylated 
proteins between fibers types, showing oxidative fibers higher accumulation of SUMO 
conjugated proteins compared to the glycolytic fibers. 
6.1.2.  SUMO reaction is perturbed in the diaphragm during CMV treatment 
The levels of total SUMO conjugated proteins are altered in stress situations due to 
changes in the expression of the SUMO enzymes in cells and organs116. We hypothesized 
that the SUMOylation will change as a consequence of acquired muscle pathology, using 
VIDD as a model. 
We compared the total levels of SUMOylated proteins for both SUMO1 and 
SUMO2/3 in the diaphragm of control and CMV treated rats. The results showed a 
progressive elevation in the total amount of SUMOylation for both SUMO1 and 
SUMO2/3 target proteins, with short times of CMV (Figure 14). 
 
Figure 14: Quantification of free and conjugated SUMO1 (A), and SUMO2/3 (B). The 
intensities of free SUMO and SUMO conjugates were obtained from western blot 
expressed in AU after normalization by the correspondent GAPDH loading. 
6.1.3.  SUMOylated proteins increase in all fiber types as a response to CMV 
Since CMV increased the total amount of SUMOylated proteins, we hypothesized that 
an increase in the SUMO conjugation in the different fiber types will be observed. We 
compared the previous cryosections from control rats with the ones obtained at different 
time points of CMV.  
We observed a progressive increase of the SUMO1 and SUMO2/3 signals with the 
treatment, being the glycolytic fibers highly affected, and reaching the same intensity 
levels as the oxidative fibers at the end of the measurements (Figure 15). 
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Furthermore, we found the presence of both SUMOs in the myonuclei in the different 
conditions, validating the nuclear localization of SUMOs previously described in the 
literature117. 
 
Figure 15: Localization of SUMO1 (A) and SUMO2/3 (B) proteins on diaphragm muscle 
cross-sections from control and mechanically ventilated rats. Cryo-sections stained for 
NADH-TR, and SUMO1-2/3 antibodies in diaphragms from control and mechanically 
ventilated rats 10 days, and with BGP-15 for 10 days (10d BGP-15). Scale bars, 50 µm.  
6.1.4.  SUMO substrates in skeletal muscle  
The specific SUMOylation levels in the muscle fibers and how they increased during 
CMV opened the question about which proteins were SUMOylated in the diaphragm 
during normal conditions and what changes undergo with the CMV treatment. 
With a combined approach of immunoprecipitation, mass spectrometry, and 
bioinformatics analysis on rat diaphragms lysates, we identified a vast amount of new 
SUMO interacting proteins involved in a wide spectrum of cellular activities with a broad 
distribution in the cell compartments. In normal circumstances, the majority of those 
proteins are involved in diverse pathways for energy production, muscle remodeling, and 
contraction. 
During the different points of mechanical ventilation, we found the recruitment of 
new SUMO1 and SUMO2/3 substrates from different processes including transcription 
factor, translation regulator activity, response to an external stimulus, and response to 
stress. These results validated our hypothesis about SUMO playing an important role in 
muscle physiology and the adaptation to pathology. 
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6.1.5.  SUMO substrates validation 
By immunoprecipitation with SUMO1 and SUMO2/3, we obtained all the SUMO 
interacting proteins, including SUMOylated proteins, proteins interacting with 
SUMOylated proteins, and proteins with SIM domains that interact with SUMO moieties. 
To confirm which of them were SUMOylated, we selected ten highly abundant SUMO-
protein candidates with different roles and localizations with a positive score in potential 
SUMO lysines, and we performed prokaryotic and eukaryotic assays. We obtained 
positive SUMOylation results for the E3 ubiquitin ligases MuRF1 and MuRF3, the motor 
protein myosin, the mitochondrial proteins aspartate aminotransferase (AATM), Ornithine 
aminotransferase (OAT), ATP synthase subunit epsilon (ATP5E), and ATP synthase 
subunit alpha (ATP5A) and for the ryanodine receptor-related proteins calsequestrin 1 
(CASQ1), calsequestrin 2 (CASQ2) and triadin (TRDN). 
In the case of myosin, calsequestrin 1, triadin, and ATP synthase subunit alpha, a 
western blot analysis performed using the enriched SUMO1 and SUMO2/3 peptide eluted 
immunocomplexes confirmed their SUMOylation in the skeletal muscle. 
6.1.6.  SUMO cycle components adapt to pathological conditions 
Previous studies suggest that stress situations induce alterations in the expression of 
the SUMO machinery components118. These alterations could be the explanation for the 
different levels in SUMOylation observed along with the CMV treatment. We performed 
a transcriptomic analysis from rat diaphragm muscle from control and CMV. The results 
showed changes in the mRNA expression levels of the SUMO cycle components in 
control and during 1, 5, and 10 days of CMV (Figure 16). 
The increased expression levels of SUMO conjugating enzymes like the E1 dimers, 
(Sae1/Uba1), the E2 (Ubc9), and some E3 ligases (Pias1-3-4, RanBP2, TOPORS), and 
the reduced levels of the E3 ubiquitin ligase RFN4 could explain the increase in the global 
SUMOylation profile. The transcriptomic values were validated for some candidates at 
the protein level via western blot or immunofluorescence in cryosections. 
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Figure 16: Transcriptome analysis of SUMO-related enzymes in control and 
mechanically ventilated rats without and with drug treatment. Quantitative PCRs 
performed on SUMOs (A), E1- and E2 SUMO enzymes (B and C), SENPs (D), STUbL 
RNF4 (E), and ATR1, TRIM63, and the circadian Per2 (F). 
6.1.7.  BGP-15 reverts the SUMOylation levels altered by CMV 
BGP-15 is a co-inducer of HSP72 expression and was useful for the cardiac function 
improvement119 and the recovery of the mitochondrial function during CMV in rat 
diaphragm120. Heat shock proteins (HSP) are overexpressed in response to stressful 
situations with a chaperone activity and a protective role against ROS121. ROS increase 
during prolonged exposure to CMV122 and high ROS levels increase SUMOylation by 
enhancing the activity of PIAS1 and PIAS4 and blocking SENPs123. 
We hypothesized that treating rats with BGP-15 while they were under CMV 
conditions could revert SUMOylation levels. We used diaphragms extracted from rats 
after 10 days of CMV and treated with BGP-15 to measure the general SUMO levels and 
compared them with non-treated rats. We observed a clear effect of BGP-15 reducing the 
total SUMOylation levels after 10 days of CMV (Figure 14), the immunofluorescence 
intensity was similar to the control slides (Figure 15), and both SUMO pathway 
components proteome and transcriptome were protected (Figure 16). 
 
  53 
6.1.8.  Conclusion of Paper I 
For the first time, we showed a heterogeneous distribution of SUMO conjugated 
proteins in the muscle fibers according to the fiber type. We observed an adaptation of the 
SUMO pathway in response to the progression of VIDD. Finally, the positive effect of 
BGP-15 impairing the pathological effect in the SUMO pathway opens the door for the 
SUMO cycle as a target for the development of a pharmacological approach in the 
treatment of pathologies. 
6.2. Paper II 
MuRF1 plays an important role in the muscle pathophysiology and we found it was 
SUMOylated by SUMO1 in paper I. MuRF1 is a muscle E3 ubiquitin ligase known to be 
involved in the muscle protein turnover124 for muscle maintenance and has a protective 
role during cardiac hypertrophy125. MuRF1 is also related to the development of protein 
aggregate myopathies (PAMs)126 and hypertrophic cardiomyopathy (HCM)127,128 when its 
protein sequence is mutated. 
We wanted to characterize the SUMO conjugation of the E3 ubiquitin ligase MuRF1 
and its implication in MuRF1 activity and localization. We also wanted to correlate the 
alterations in MuRF1 SUMOylation and its association with muscle pathologies. 
6.2.1.  SUMO1 conjugates MuRF1 on lysine 238 
Knowing that MuRF1 is SUMOylated, we tried to find the exact lysine in the MuRF1 
sequence involved in the SUMO conjugation. With a combination of bacteria 
SUMOylation assay, immunoprecipitation, and mass spectrometry followed by 
bioinformatics analysis we isolated ten potential lysines involved in the SUMOylation of 
MuRF1. 
To define which lysine could be involved in the SUMO conjugation, we generated 
single mutations for all the ten identified lysines (K) into arginine along the GFP-MuRF1 
amino acid sequence and performed eukaryotic assays. Exclusively, the GFP-MuRF1 
containing the mutation in the 238 position showed a complete absence of the slow 
migrating bands above the native GFP-MuRF1 protein, and this result was confirmed by 
the total absence of PTM bands above GFP-MuRF1 corresponding to SUMO1 after 
immunoprecipitation. 
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This result suggests that K238 is the unique lysine in the MuRF1 protein that could 
become a target of SUMO1 conjugation (Figure 17). 
 
Figure 17: MuRF1 protein structural domains indicated in different colors, RING, MFC 
(MuRF family conserved domain), B-box, CC (coiled coin, and COS domains), AR 
(acidic tail). Potential SUMOylation binding sites for single mutants generation marked in 
orange.  
6.2.2.  Ubc9 and PIAS 4 promote the SUMOylation on MuRF1 
The correct SUMO conjugation into the target proteins is mediated by an enzymatic 
pathway as it was earlier mentioned. Such conjugation requires the use of the only known 
E2 conjugation enzyme Ubc9 and maybe the use of an E3 SUMO ligase. To identify the 
enzymes involved in MuRF1 SUMOylation, we performed eukaryotic assays with the co-
transfection of GFP-MuRF1 with Ubc9 or several E3 SUMO ligases. An increase in the 
SUMOylated fraction of MuRF1 when combined with Ubc9 but not with its catalytic 
mutant (C93S) and with the specific use of the E3 SUMO ligase PIAS4 validated both 
enzymes. 
6.2.3.  MuRF1 mutation impairs its enzymatic activity for troponin 
degradation 
Mutations in the polypeptide chain sequence can affect the protein 3D structure and 
inactivate it. We hypothesized that alterations in the MuRF1 sequence influence its 
activity. To address this question, we compared the MuRF1 wild type (wt) with the 
K238R in the enzymatic degradation of a well-known target, troponin.  
We observed that the degradation of troponin was significantly reduced in MuRF1 
K238R compared to the wt. This result suggested that the mutation affects the substrate 
ubiquitination, probably due to a conformational protein change. This change in 
conformation could generate a non-functional E3 ubiquitin ligase or cause an impairment 
between enzyme-substrate interaction. 
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6.2.4.  SUMOylation is essential for MuRF1 translocation into the nucleus 
Since SUMOylation promotes cellular translocation we focused our next goal in the 
analysis of the cellular distribution of MuRF1 in mouse myoblasts. We compared the 
cellular distribution of transfected GFP tagged MuRF1 wt and K238R in C2C12 cells 
using cell fractionation and immunofluorescence imaging. The results showed that 
SUMO1 conjugation to MuRF1 was required to translocate into the nucleus even though 
it was cleft after and that the K238R mutation induced a high proliferation of MuRF1 
aggregates in the cytoplasm (Figure 18). 
 
Figure 18: Confocal microscopy analysis of GFP-MuRF1 and GFP-MuRF1-K238R 
cellular localization. Protein distributed in cytoplasm and nuclei, in mitochondria, or 
forming aggregates in the cytoplasm (A). Statistical distribution of protein localization in 
transfected cells (B). White squares show enhanced details, arrows show alteration in 
mitochondria morphology due to increased ROS levels. Scale bar 10 µm. 
6.2.5.  MuRF1 protects from SUMO deconjugation under high glucose 
conditions 
To investigate the potential role and the biological significance of MuRF1 localization 
in mitochondria, we analyzed the level of total SUMOylated proteins in murine 
myoblasts. We compared no transfected cells with ones transfected with MuRF1 wt and 
K238R placed in normal (5,5 mM glucose) and high glucose medium (25 mM glucose). 
A significant decrease in the SUMO2/3 conjugated proteins signal was detected in no 
transfected cells or K238R ones in high glucose compared to normal glucose, but no 
difference was noticed in cells overexpressing MuRF1 wt. This result was connected with 
a reduction of approximately 50% of cellular ROS in the cells transfected with wt 
MuRF1, demonstrating that MuRF1 had a positive effect preserving the SUMOylation of 
cellular proteins by reducing the level of cellular ROS. 
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6.2.6.  Conclusion 
The new insights provided on MuRF1 SUMOylation highlight the critical role played 
by SUMO1 in the modulation of both MuRF1 activity and localization. Since the specific 
lysine involved in the SUMO conjugation is localized in the coiled-coil region of MuRF1, 
with the role of microtubule association, the effect caused by SUMOylation impairment 
could affect the correct localization of MuRF1. 
6.3. Paper III 
The knowledge provided by our previous work done on paper I showed that 
SUMOylated proteins accumulate in different degrees according to the muscle fiber type. 
We also observed that VIDD causes alterations in the expression levels of the SUMO 
machinery components and at the end alterations in the global SUMO conjugation. 
In this paper, we wanted to investigate if the correlation between SUMOylation levels 
and fiber type found in the diaphragm was also observed with other muscles along the 
body. Also, if a new stress situation caused by soleus unloading had a similar effect on the 
SUMOylation levels as CMV. 
6.3.1.  The SUMO system is specific to each skeletal muscle 
To understand if there were variations among the different skeletal muscles in their 
SUMOs profile, we compared the SUMO1 and SUMO2/3 western blots obtained from 
the lysates of nine different rat skeletal muscles (tibialis anterior, EDL, soleus, diaphragm, 
plantaris, gastrocnemius superficial, gastrocnemius deep, gastrocnemius proximal and 
masseter). We found variations in the intensity levels of the SUMO substrate conjugation 
associated with the different skeletal muscles. These results confirmed our hypothesis that 
the SUMO pathway adapts to the needs of the skeletal muscles according to the specific 
role played by each one of them. 
6.3.2.  SUMO conjugation levels are specific according to skeletal muscle fiber 
In the paper I, we observed a mosaic distribution of SUMOylated proteins in the 
diaphragm connected with the metabolism of the muscle fibers. We hypothesized that the 
other skeletal muscles would have a similar distribution with a muscle fiber type 
correlation and the abundance of SUMO conjugates. 
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Immunostaining analysis with SUMO1 or SUMO2/3 antibodies, and ATPase pH 
10.4, and NADH-TR stainings, performed in consecutive cryosections from ambulatory 
rats, provided a mosaic of fluorescence intensities with higher levels of SUMOylation 
localized in the skeletal muscle fibers with an oxidative metabolism (Figure 19). 
 
Figure 19: Fluorescence intensity measurement for each fiber type. 100 fibers per type 
from the nine different skeletal muscles were used in the analysis. Results were 
normalized to the corresponding myofiber area and values were expressed in arbitrary 
units (A.U.). 
These results validated our previous findings in the paper I where we showed the 
same distribution of SUMOylated proteins in the diaphragm. 
6.3.3.  Transcriptome analysis of the SUMO machinery components 
For a better understanding of the heterogeneity in the SUMOylation expression in the 
different skeletal muscles, we analyzed the transcriptomic levels of the SUMO moieties 
and enzymes from the same nine rat skeletal muscles. The RNA measurements showed 
differences in their expression levels within the skeletal muscles. The proteomics analysis 
confirmed the results from the transcriptomics, validating the correlation of the SUMO 
enzymes expression and the specific function of the skeletal muscles. 
The principal component analysis provided with interesting information. The different 
expressions of the SUMO components allowed us to classify skeletal muscles according 
to muscle embryogenesis, anatomical position (vertical), and fiber type composition 
(horizontal) (Figure 20). 
 58 
 
 
Figure 20: Principle component analysis of transcriptome reveals the formation of 
distinct clusters, indicating differences in the SUMO expression signature. 
6.3.4.  Muscle activity impairment affects SUMOylation levels 
The previous experiments were performed over healthy, ambulatory rats and we 
wanted to observe the effect of a different pathology over the SUMO pathway. In the 
paper I, we observed changes in the SUMO pathway due to CMV in rat diaphragm, so we 
hypothesized that other alterations in the muscle activity could induce modifications in 
the expression of the SUMO network components and therefore changes in the general 
SUMOylation levels. 
Using soleus muscle extracted from ambulatory and tailed-suspended Wistar-Han rats 
during 1, 2, and 4 days of unloading, we performed a western blot analysis of SUMO1 
and SUMO2/3 followed by the transcriptomic analysis of the SUMO machinery. To 
complete the study, an immunohistochemistry study of cryosections was performed. 
Results showed an increase of SUMOylation levels combined with alterations in the 
enzymes right after unloading before any signs of protein degradation mediated by the 
UPS. This could be explained by a protective effect of the SUMO pathway in the proteins 
by delaying its ubiquitination and further protein degradation (Figure 21). 
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Figure 21: Principle component analyses depicting the effect of unloading the SUMO 
machinery. Note that expression of SUMO related factors changes rapidly within 1 day 
after unloading. 
6.3.5.  PAX6 increase Ubc9 expression in early events of muscle inactivity 
In our papers studying the effect of muscle stress in the SUMO levels (papers I and 
III), we observed an increase in the SUMO conjugated proteins in parallel with the 
treatment at the same time as Ubc9 is overexpressed. 
Deeper bioinformatics inquires of the Ubc9 promoter region gave us a list with 
potential transcription factors including HTF, ARP1, and ATF. We recognized PAX6 as a 
candidate among them and investigated its expression levels and localization by western 
blot and immunohistochemistry. 
Interestingly the overexpression of Ubc9 was not connected to PAX6 overexpression 
but to its accumulation in the nucleus during short times of unloading. Besides we found 
that PAX6 could be SUMOylated as it is mentioned in the bibliography129, which might 
explain its translocation to the nucleus. 
6.3.6.  Conclusion 
We have validated the role of the SUMO network and the expression levels of each 
component linked to the functional requirements of each muscle according to its fiber 
type composition. 
Again, we confirmed the importance of the SUMO network and its alteration during 
muscle pathologies and the possibility of becoming a therapeutic target to alleviate the 
effects of atrophy. For that effect, we showed how PAX6 is involved in the control of 
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Ubc9 expression and its potential use as a target for the regulation of the SUMO 
conjugation. 
6.4. Paper IV 
In this manuscript, we wanted to understand the involvement of the SUMO pathway 
in the regulation of muscle regeneration. Muscle regeneration is one of the outcomes of 
myogenesis along with embryonic muscle development and postnatal growth. In all the 
situations myoblasts follow a very tightly controlled program that leads to the formation 
of myofibers. Finally, we developed an in vitro model using high glucose concentrations 
to study muscle regeneration under hyperglycemic condition, similar to the ones observed 
in diabetic patients. Our hypothesis was that this condition will cause changes in the 
normal behavior of the SUMO pathway.  
6.4.1.  SUMO conjugation changes with the progression of myogenesis 
To answer our question about the effect of the myogenesis progress in the SUMO 
conjugation we performed an analysis of SUMOylated proteins during the different time 
points studied (exponential, confluent, and 1, 3, and 5 days of myogenesis). We observed 
a peak in the proteins SUMOylated by SUMO1 and SUMO2/3 in the confluence stage 
followed by a progressive decrease during myogenesis. 
6.4.2.  The effect of hyperglycemia during myogenesis 
To understand the effect of hyperglycemia in global SUMOylation levels during 
myoblast differentiation, mouse myoblasts were grown and differentiated in normal (NG) 
and high glucose (HG) medium and monitored at the different time points mentioned. 
Myotubes developed faster in the HG, they were bigger, and with a higher nuclei count 
compared with the NG ones. They also started contracting and reached the senescence 
status earlier.  
SUMOylation levels analyzed by western blot also showed a tendency in the decrease 
of SUMOylated proteins along with the development of myogenesis but with maintained 
higher levels for both SUMO1 and SUMO2/3 in the case of HG.  
The alteration in the SUMO pattern matched the results obtained by the transcriptome 
analysis. We found that the gene expression of the SUMO network was rearranged, and 
transcripts levels were easily clustered into NG or HG conditions. 
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6.4.3.  ROS role during myogenesis 
ROS have a crucial function as secondary messengers for a multitude of pathways130, 
and even the SUMO components are regulated by them131. We pursued the investigation 
of the ROS levels during the different stages of myogenesis with and without the 
influence of a high glucose concentration.  
The results obtained from the measurement of both cytoplasmic and mitochondrial 
ROS during the different time points of myogenesis showed alteration of ROS levels. In 
normal conditions, both cytoplasmic and mitochondrial ROS had a higher peak on day 1 
and then decrease. However, in the case of high glucose conditions, the ROS peak was 
reached in the exponential phase and was maintained until the end of the experiment.  
This effect was also associated with the early senescence of the myotubes grown in 
high glucose combined with a disorganized pattern of the striation in the sarcomeric 
structure (Figure 22).  
 
Figure 22: Confocal images of myotubes derived from C2C12 cells after 5 days from the 
differentiation, in NG and HG. Samples were double-stained for fast myosin (F-Myosin, 
red) and slow myosin (S-Myosin, red) together with alpha-actinin (green); the sarcomere 
structure showed partial co-localization with myosin and alpha-actinin (yellow). The 
selected areas (white square) were magnified on the right side. Scale bars = 100 μm, scale 
bars = 10 μm for the magnified images. 
6.4.4.  Anacardic acid protects against hyperglycemia 
We have described that SUMOylation plays an important role in the myogenesis 
process and a pharmacological approach for the reversion of the SUMOylation mediated 
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by SUMO2/3 levels could help the myogenesis in hyperglycemic conditions. This 
approach could be mediated by the use of SUMOylation inhibitors like anacardic acid or 
topotecan.  
The combination of the myogenesis development in NG and HG with the addition of 
the drugs demonstrated our hypothesis but only in the case of the anacardic acid. The use 
of topotecan had not the expected positive effect over the myogenesis since it interfered 
with myoblast fusion. The SUMOylation pattern of the myoblast grown in HG with 
anacardic acid had a significant reduction in the intensity and it was similar to the ones 
grown in NG. We also observed a similar myogenesis development, with no early 
senescence and a normal sarcomeric distribution. Finally, the proteomic and 
transcriptomic expression levels of the SUMO components were similar to the ones of 
cells growing in normal conditions (Figure 23). 
 
Figure 23: Principle component analysis of transcriptome revealed the formation of two 
distinct clusters, indicating differences in SUMO expression signature during myogenesis.  
6.4.5.  SET7/9 regulation by SUMO2/3 
The regulation mediated by SUMO2/3 of the histone-lysine N-methyltransferase 
SET7/9 was previously described for the sarcomeric organization132. We use this property 
to our benefit and performed the immunoprecipitation of SET7/9 in the different 
conditions (NG, HG with and without anacardic acid) and our findings confirmed that 
only in HG conditions SET7/9 was SUMOylated and therefore inactivated. The treatment 
with anacardic acid reduced the SUMO conjugation of SET7/9. 
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6.4.6.  Conclusion 
These results seem to link the correct SUMOylation levels with a viable myogenesis 
process. We also confirmed that during hyperglycemic conditions myogenesis was 
accelerated and senescence was reached earlier than in normal conditions due to a starting 
point with higher ROS levels. 
The transcriptomic and proteomic expression levels of the SUMO machinery 
components were altered due to the excessive ROS production by the HG conditions, but 
this effect could be ameliorated using anacardic acid thanks to its properties as SUMO 
inhibitor and antioxidant. 
Finally, we linked the increase of SUMOylation produced by high glucose with the 
SUMOylation of SET7/9, an important player in myogenesis regulation. The inhibition 
mediated by SUMO conjugation of SET7/9 activity as a transcriptor factor caused the 
disorganization of the sarcomeric structures. 
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7. DISCUSSION  
One of the major problems with muscle pathologies is the lack of early detection 
events to provide immediate treatments. Diseases like muscular dystrophies and 
inflammatory myopathies begin to develop years before their diagnosis, and by the time 
patients suffer the symptoms, only palliative treatments are available. Traditional methods 
of diagnosis include medical history, blood, and genetic tests, biopsies, and imaging. The 
development of new ways for the early detection of pathologies could help with the 
prognosis. 
This thesis provides new potential results for an early diagnosis approach for skeletal 
muscle pathologies, considering the protein regulation mediated by SUMO 
posttranslational modification. Our discovery shows that SUMO enzymes and the global 
SUMOylation process are quickly altered before the activation of protein degradation, in 
the starting phases of the three muscle disorders described (VIDD, muscle inactivity, and 
muscle regeneration in hyperglycemia). Indeed, the expression of some SUMO enzymes 
can be used as biomarkers for the premature detection of muscle pathologies as we 
confirmed in the rat diaphragm and soleus, and in the vastus lateralis from humans.  
Until now, we only had access to few animal models of acquired pathologies, 
however extra studies in animals with inherited myopathies or in human muscle biopsies 
are needed to confirm the potential use of the SUMO network components as biomarkers.  
Regulate the SUMO conjugation in our favor can be beneficial for treating patients. 
An extended analysis of PAX6 role regulating the expression of Ubc9 during muscle 
diseases is necessary to confirm its effect. The development of a pharmacological 
approach to increase o decrease the presence of PAX6 in the myonucleus could interfere 
with the SUMO conjugation levels through the control of Ubc9 expression and reduce or 
block harmful effects of muscle inactivity. 
We discovered a vast amount of new classes of protein related to SUMO. This result 
emphasizes how crucial is the SUMO pathway role in the regulation of muscle functions. 
In-depth analysis performed with some candidates showed the potential protective effect 
against degradation of myosin mediated by SUMO conjugation. More, we confirmed the 
role of SUMOylation of the E3 ubiquitin ligase MuRF1 in lysine 238 and compared the 
negative effect of the SUMOylation impairment in terms of activity and cell localization 
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which can be associate to hypertrophic cardiomyopathy and protein aggregate 
myopathies. Also, we described one potential molecular mechanism describing the 
alterations in the myogenesis process in hyperglycemia; the transcriptor factor SET7/9 
becomes inactivated through SUMOylation and impairs muscle regeneration in high 
glucose conditions. Finally, other SUMO related candidates associated to the calcium 
regulation events (ryanodine receptor, calsequestrin, and triadin), and mitochondrial 
proteins (aspartate aminotransferase, ornithine aminotransferase, ATP synthase subunits-α 
and -ε) were not yet studied, but their involvement in the muscle contraction makes them 
valuable new SUMO targets for potential implication in physiology and myopathies 
studies. 
The positive effect of some drugs, as BGP-15 observed in diaphragm from 
mechanically ventilated rats, and anacardic acid for the treatment of myogenesis in 
hyperglycemic conditions validates our hypothesis that targeting the SUMO network will 
ameliorate the effects of some SUMO-related muscle pathologies. The screening of new 
drugs to interfere with the SUMOpathway will provide new pharmacological approaches 
in the treatment of muscle diseases. 
Future perspectives involve a deeper analysis of the previous findings: 
Develop a CRISP-CAS9 methodology in murine or human myoblasts and generate 
transgenic mouse models with mutations in the SUMO protein consensus domain will 
allow us to understand the physiological function of SUMO PTM to the investigated 
skeletal muscle proteins. To complete the SUMO PTM picture, a unique mouse model 
with inducible expression of UBC9 will give us a better insight into the implications of 
SUMOylation in the regulation of different skeletal muscle activities. 
A specific study of MuRF1 mutations associated with human pathologies found close 
to the SUMO binding site could explain the implication of this E3 ubiquitin ligase in the 
development of human diseases like hypertrophic cardiomyopathy and protein aggregate 
myopathies. 
Cancer is one of the pathologies that beneficiates more for the early diagnosis, 
increasing the chances for successful treatment. Our future project combines the study of 
the alterations in SUMO conjugation and the myogenesis dysregulation in 
rhabdomyosarcoma and the test of new drugs targeting the SUMO pathway.  
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